

Amendments to the Specification:

On page 1, please replace the title with the following new title:

--METHOD OF TREATING IMMUNE DISEASE--

Replace the paragraph on page 7, lines 11-30, with the following paragraph:

The above methods include the use of a growth factor receptor antibody or a hormone receptor antibody to target to end-organs bearing such receptor(s), the functions of which can be blocked with said antibodies. An isotopic or drug conjugate of these antibodies can also be used to deliver a therapeutic agent to said tissues and organs, in order to affect diseases of tissues which bear such receptors. For example, in endometriosis, involving ectopic endometrial tissue, the current standard drug therapy involves administration of a synthetic steroid derived from ethisterone (~~DANOCRINE~~ DANOCRINE[®] brand of danazol), which is chemically a 17-alpha-Pregna-2,3-dien-20-yno[2,3,3-d]-isoxazol-17-ol. This probably acts, at least in part, on sex steroid metabolism and with sex hormone receptors, particularly follicle-stimulating hormone (FSH) and luteinizing hormone (LH) at the target organ. It is now possible to use an antibody against these gonadal steroid receptors, alone or as an immunoconjugate with isotopes, drugs, toxins, hormone antagonists, cytokines, autocrines, etc., to inactivate and make the ectopic endometrium atrophic.

Replace the paragraph on page 22, line 34 to page 23, line 2, with the following paragraph:

These agents include WR-2721 (S2-[3-aminopropylamino]ethylphosphorothioic acid), known as ~~Ethyol~~ Ethyol[®] being developed by US Bioscience, WR-2721's dephosphorylated metabolite, WR-1065, and MGI 136 being developed by MGI Pharma Inc.